APTX - Aptinyx commences Phase 2b study of NYX-783 in patients with PTSD

Aptinyx (NASDAQ:APTX) has initiated a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD). Shares up 2.9% premarket at $2.80. The company anticipates reporting data from the Phase 2b study in H2 2023. The NYX-783 Phase 2b PTSD program will consist of two separate studies at two dose levels: 50 mg and 150 mg, each enrolling ~300 patients. The primary efficacy endpoint of each study will be the change from baseline in the Clinician-Administered PTSD Scale for the DSM-5 (CAPS-5) Total score. Key secondary endpoints in both studies will include various measures of global impression of severity and improvement (CGI-S, CGI-I, PGI-S, PGI-I).

For further details see:

Aptinyx commences Phase 2b study of NYX-783 in patients with PTSD